Investigation of some factors contributing to negative food effects

Biopharmaceutics and Drug Disposition

Volumn 30, Issue 2, 2009, Pages 71-80

  Marasanapalle, Venugopal P ^a   Crison, John R ^b   Ma, Jingwen ^c   Li, Xiaoling ^a   Jasti, Bhaskara R ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b Simulations Plus Inc   (United States)

^c PFIZER INC   (United States)

Author keywords

Caco 2; Food effect; Mechanisms; Physicochemical; SPIP

Indexed keywords

ATENOLOL; BIDISOMIDE; CAPTOPRIL; CHLOROTHIAZIDE; CIMETIDINE; DICLOFENAC; DIGOXIN; DILTIAZEM; ETOPOSIDE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IBUPROFEN; INDOMETACIN; KETOPROFEN; METFORMIN; METOPROLOL; NADOLOL; NAPROXEN; NIFEDIPINE; PHENYTOIN; PRAVASTATIN; PREDNISOLONE; PROPRANOLOL; QUINIDINE; STAVUDINE; TACRINE; THEOPHYLLINE; UNINDEXED DRUG; VALPROIC ACID; ZIDOVUDINE; DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DIET RESTRICTION; DRUG ABSORPTION; DRUG PENETRATION; DRUG SOLUBILITY; FEMALE; FOOD; FOOD DRUG INTERACTION; HUMAN; HUMAN CELL; IONIZATION; MALE; NONHUMAN; PH; PHYSICAL CHEMISTRY; POSTPRANDIAL STATE; RAT; UPPER GASTROINTESTINAL TRACT; ANIMAL; INTESTINE ABSORPTION; METABOLISM; PERMEABILITY; PHYSIOLOGY; SOLUBILITY; WISTAR RAT;

ANIMALS; AREA UNDER CURVE; CACO-2 CELLS; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MALE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; POSTPRANDIAL PERIOD; RATS; RATS, WISTAR; SOLUBILITY;

EID: 63049114272     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.647     Document Type: Article

References (41)

1. Read NW, Sugden K. Gastrointestinal dynamics and pharmacology for the optimum design of controlled-release oral dosage forms. Crit Rev Ther Drug Carrier Syst 1988; 4: 221-263.
2. CDER. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. 2002, FDA.
3. Welling PG. Effects of food on drug absorption. Pharmacol Ther 1989; 43: 425-441.
4. Welling PG. Effects of food on drug absorption. Annu Rev Nutr 1996; 16: 383-415.
5. Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999; 37: 213-255.
6. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 1999; 36: 233-254.
7. Midha KK, McKay G, Rawson MJ, Korchinski ED, Hubbard JW. Effects of food on the pharmacokinetics of methylphenidate. Pharm Res 2001; 18: 1185-1189.
8. Thummel KE, Kunze KL, Shen DD. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 1997; 27: 99-127.
9. Pao LH, Zhou SY, Cook C, et al. Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-administration: relationship with region-dependent intestinal absorption. Pharm Res 1998; 15: 221-227.
10. Shiau, YF, Fernandez P, Jackson MJ, McMongale S. Mechanisms maintaining a low-pH microclimate in the intestine. Am J Physiol 1985; 248: G608-G617.
11. Charman WN, Porter CJ, Mithani S, Dressman JB. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 1997; 86: 269-282.
12. Welty DF, Siedlik PH, Posvar EL, Selen A, Sedman AJ. The temporal effect of food on tacrine bioavailability. J Clin Pharmacol 1994; 34: 985-988.
13. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998; 15: 11-22.
14. Shepard DR, Mani S, Kastrissios H, et al. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol 2002; 49: 398-402.
15. Kasim NA, Whitehouse M, Ramachandran C, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004; 1: 85-96.
16. Varma MV, Panchagnula R. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: Kinetic analysis of quinidine efflux in situ. J Pharm Sci 2005; 94: 2632-2643.
17. Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998; 15: 698-705.
18. Levis KA, Lane ME, Corrigan OI. Effect of buffer media composition on the solubility and effective permeability coefficient of ibuprofen. Int J Pharm 2003; 253: 49-59.
19. Serajuddin AT, Sheen PC, Mufson D, Bernstein DF, Augustine MA. Preformulation study of a poorly water-soluble drug, alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: selection of the base for dosage form design. J Pharm Sci 1986; 75: 492-496.
20. Crison JR, Weiner ND, Amidon GL. Dissolution media for in vitro testing of water-insoluble drugs: effect of surfactant purity and electrolyte on in vitro dissolution of carbamazepine in aqueous solutions of sodium lauryl sulfate. J Pharm Sci 1997; 86: 384-388.
21. Cowan DS, Hicks KO, Wilson WR. Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br J Cancer Suppl 1996; 27: S28-S31.
22. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 1998; 15: 1160-1167.
23. Varma MV, Sarkar M, Kapoor N, Panchagnula R. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs 1. Simultaneous determination of quinidine and permeability markers in rat in situ perfusion samples. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 816: 243-249.
24. Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res. 1995; 13: 1336-1342.
25. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernas H, Karlen A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem 1998; 41: 4939-4949.
26. Tavelin S, Taipalensuu J, Soderberg L, Morrison R, Chong S, Artursson P. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm Res 2003; 20: 397-405.
27. Parrott N, Lave T. Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. Eur J Pharm Sci 2002; 17: 51-61.
28. Markowska M, Oberle R, Juzwin S, Hsu CP, Gryszkiewicz M, Streeter AJ. Optimizing Caco-2 cell monolayers to increase throughput in drug intestinal absorption analysis. J Pharmacol Toxicol Methods 2001; 46: 51-55.
29. Beermann B, Groschinsky-Grind M. Gastrointestinal absorption of hydrochlorothiazide enhanced by concomitant intake of food. Eur J Clin Pharmacol 1978; 13: 125-128.
30. Davies NM. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 1998; 34: 101-154.
31. Al-Habet SM, Rogers HJ. Effect of food on the absorption and pharmacokinetics of prednisolone from enteric-coated tablets. Eur J Clin Pharmacol 1989; 37: 423-426.
32. Lee KJ, Johnson N, Castelo J, et al. Effect of experimental pH on the in vitro permeability in intact rabbit intestines and Caco-2 monolayer. Eur J Pharm Sci 2005; 25: 193-200.
33. Pade V, Stavchansky S. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm Res 1997; 14: 1210-1215.
34. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs 2002; 62: 1481-1502.
35. Martin A, Bustamante P, Chun CH, A. Physical Pharmacy-Physical Chemical Principles in the Pharmaceutical Sciences. Waverly International: Baltimore, MD, 1994; 362-393.
36. Nagahara N, Tavelin S, Artursson P. Contribution of the paracellular route to the pH-dependent epithelial permeability to cationic drugs. J Pharm Sci 2004; 93: 2972-2984.
37. Serajuddin AT, Ranadive SA, Mahoney EM. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci 1991; 80: 830-834.
38. Pan HY, DeVault AR, Brescia D, et al. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 1993; 31: 291-294.
39. Lennernas H. Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation? Pharm Res 1995; 12: 1573-1582.
40. Neuhoff S, Ungell AL, Zamora I, Artursson P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res 2003; 20: 1141-1148.
41. Marathe PH, Greene DS, Kollia GD, Barbhaiya RH. Evaluation of the effect of food on the pharmacokinetics of avitriptan. Biopharm Drug Dispos 1998; 19: 381-394.